Table 3.
Procedural details in different treatment groups.
| Variable | EVT - Selective Stenting | EVT- Routine Stenting | CFE |
|---|---|---|---|
| n (%) |
n (%) | n (%) | |
| Total stents | 123 | 330 | 552∞ |
|
| |||
| Balloon-Expandable stents | 15/110 (13.6) # | 93 (28.2) | DNA |
|
| |||
| Self-Expandable stents | 95 /110 (86.4) # | 237 (71.8) | DNA |
|
| |||
| Bioabsorbable stents | 0 (0) | 41 (12.4) | DNA |
|
| |||
| Covered stents | 0 (0) | 17 (5.1) | DNA |
|
| |||
| Atherectomy | 72 (10.6) | 15 (4.9) | DNA |
|
| |||
| Contralateral cross-over approach | 479 (70.6) | 239 (78.1) | DNA |
|
| |||
| Ipsilateral retrograde approach | 104 (15.3) | 38 (12.4) | DNA |
|
| |||
| Stent Fracture | 0 (0) | 6 (1.8) | DNA |
|
| |||
| Stent Re puncture | 2 (1.6) | 24 (7.2) | DNA |
|
| |||
| CFE only | DNA | DNA | 944 (48.9) |
|
| |||
| Hybrid CFE (CFE + endovascular procedure) | DNA | DNA | 794 (41.1) |
|
| |||
| CFE + Distal Revascularization | DNA | DNA | 401/1721 (23.3) ƍ |
|
| |||
| CFE + Proximal Revascularization | DNA | DNA | 495/1721 (28.7) ƍ |
|
| |||
| CFE + Proximal and Distal Revascularization | DNA | DNA | 81/1683 (4.8) π |
|
| |||
| Patch angioplasty | DNA | DNA | 1325/ 1837 (72.1) ∗ |
|
| |||
| Profundaplasty | DNA | DNA | 414/743 (55.7) φ |
|
| |||
| Concomitant Bypass | DNA | DNA | 110 (5.6) |
[# 7 out of 8 studies | π 11 out of 13 studies | ƍ 12 out of 13 studies | ∗ 12 out of 13 studies | ∞ concomitant proximal or distal stents (not in CFA)] DNA-Does not apply.